Gastroesophageal reflux after per oral endoscopic myotomy for achalasia: results of a monocentric cohort.

Gastro-esophageal reflux achalasia esophagitis per-oral endoscopic myotomy

Journal

Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659

Informations de publication

Date de publication:
05 Aug 2024
Historique:
received: 15 06 2024
accepted: 03 08 2024
medline: 8 8 2024
pubmed: 8 8 2024
entrez: 7 8 2024
Statut: aheadofprint

Résumé

Peroral endoscopic myotomy (POEM) has become the first line treatment for achalasia, but controversies remain about the prevalence of gastro-esophageal reflux disease (GERD) after the procedure. The aim of this study was to evaluate post-POEM GERD by a retrospective analysis of a single center cohort. Achalasia patients aged 18 or above, who underwent POEM between 2012 and 2021, were included, provided they had an endoscopic control of reflux at least one year after POEM. GERD symptoms based on GerdQ questionnaire, and proton pomp inhibitors (PPI) consumption were also evaluated. Among a consecutive cohort of 422 patients treated by POEM, 254 patients were included. Endoscopic results were available after a mean follow-up of 1.9 ± 1.5 years. 71/254 patients (28 %) had erosive esophagitis (86 % Los Angeles Grade A or B). At the last follow-up (mean 4.5 ± 2.2 years), clinical success of POEM (Eckardt score ≤ 3) was achieved in 79.5 % of patients. 44.5 % of patients were on PPI. Mean GerdQ score was 2.2 ± 2.7, with only 13 patients (6.5 %) with a score ≥ 8. In this cohort of achalasia patients with an endoscopic follow-up at least 1 year after POEM, GERD did not appear a major threat concern: clinical symptoms were mild in most cases, as was the degree of erosive esophagitis. Furthermore, at the time of last follow up, less than half of patients required treatment with PPI.

Sections du résumé

BACKGROUND AND STUDY AIMS OBJECTIVE
Peroral endoscopic myotomy (POEM) has become the first line treatment for achalasia, but controversies remain about the prevalence of gastro-esophageal reflux disease (GERD) after the procedure. The aim of this study was to evaluate post-POEM GERD by a retrospective analysis of a single center cohort.
PATIENTS AND METHODS METHODS
Achalasia patients aged 18 or above, who underwent POEM between 2012 and 2021, were included, provided they had an endoscopic control of reflux at least one year after POEM. GERD symptoms based on GerdQ questionnaire, and proton pomp inhibitors (PPI) consumption were also evaluated.
RESULTS RESULTS
Among a consecutive cohort of 422 patients treated by POEM, 254 patients were included. Endoscopic results were available after a mean follow-up of 1.9 ± 1.5 years. 71/254 patients (28 %) had erosive esophagitis (86 % Los Angeles Grade A or B). At the last follow-up (mean 4.5 ± 2.2 years), clinical success of POEM (Eckardt score ≤ 3) was achieved in 79.5 % of patients. 44.5 % of patients were on PPI. Mean GerdQ score was 2.2 ± 2.7, with only 13 patients (6.5 %) with a score ≥ 8.
CONCLUSION CONCLUSIONS
In this cohort of achalasia patients with an endoscopic follow-up at least 1 year after POEM, GERD did not appear a major threat concern: clinical symptoms were mild in most cases, as was the degree of erosive esophagitis. Furthermore, at the time of last follow up, less than half of patients required treatment with PPI.

Identifiants

pubmed: 39111576
pii: S2210-7401(24)00161-X
doi: 10.1016/j.clinre.2024.102440
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102440

Informations de copyright

Copyright © 2024. Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Laurine Estermann (L)

Université de Lorraine, CHU de Nancy, Hepatogastroenterology Department, Nancy, France; Université de Lyon, Hospices Civils de Lyon, Hospital E. Herriot, Digestive Physiology Department, Lyon, France.

Sophie Testu (S)

Université de Lyon, Hospices Civils de Lyon, Hospital E. Herriot, Digestive Physiology Department, Lyon, France.

Jérôme Rivory (J)

Université de Lyon, Hospices Civils de Lyon, Hospital E. Herriot, Hepatogastroenterology Department, Lyon, France.

Florian Rostain (F)

Université de Lyon, Hospices Civils de Lyon, Hospital E. Herriot, Hepatogastroenterology Department, Lyon, France.

Thierry Ponchon (T)

Université de Lyon, Hospices Civils de Lyon, Hospital E. Herriot, Hepatogastroenterology Department, Lyon, France.

Mathieu Pioche (M)

Université de Lyon, Hospices Civils de Lyon, Hospital E. Herriot, Hepatogastroenterology Department, Lyon, France.

Sabine Roman (S)

Université de Lyon, Hospices Civils de Lyon, Hospital E. Herriot, Digestive Physiology Department, Lyon, France.

François Mion (F)

Université de Lyon, Hospices Civils de Lyon, Hospital E. Herriot, Digestive Physiology Department, Lyon, France. Electronic address: francois.mion@chu-lyon.fr.

Classifications MeSH